Brief: Iterum Therapeutics Announces Special Protocol Assessment Agreement With FDA
11/07/2022 14:26
July 11 (Reuters) - Iterum Therapeutics PLC ITRM.O :
* ITERUM THERAPEUTICS ANNOUNCES SPECIAL PROTOCOL ASSESSMENT
(SPA)
AGREEMENT WITH THE FDA
* ITERUM THERAPEUTICS PLC - CLINICAL TRIAL EXPECTED TO BEGIN
ENROLLMENT IN Q4 2022
* ITERUM THERAPEUTICS PLC - SPA SUPPORTS PROTOCOL FOR PHASE
3
CLINICAL TRIAL OF ORAL SULOPENEM FOR TREATMENT OF UNCOMPLICATED
URINARY TRACT INFECTIONS
Source text for Eikon: ID:nGNX4fV1c
Further company coverage: ITRM.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Iterum Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Entergy, US natgas stocks, Brown-Forman, Datacentrex
U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Iterum Therapeutics plummets after filing wind up petition
Iterum seeks court-led dissolution amid cash crisis, inability to raise funds (updated)
Iterum files wind-up petition due to limited cash, inability to raise equity